-

FEops Simulation Technology Supports TRiCares From Initial Design Concepts to a Successful First-in-human

GENT, Belgium--(BUSINESS WIRE)--FEops, a leader in predictive planning for structural heart interventions, is proud to announce that its simulation technology supported TRiCares from initial design concept to a successful first-in-human of the Topaz Tricuspid Valve Replacement (TTVR) system, developed by TRiCares SAS. This is a major step forward towards predictive simulation-based TTVR procedure planning.

The digital twin simulation technology for TTVR was developed by FEops and already utilized by TRiCares from the early R&D phase onwards of the Topaz TTVR device. FEops created a complete virtual environment in its FEops HEARTguide research version allowing to implant a faithful device replica (validated through experimental tests) into the patients’ digital twin extracted from the medical images over the full cardiac cycle. The cyclic motion of the heart applied to the device model gives unique insights into possible migration of the implant and the identification of critical spots in the design of the device. “This is a unique approach to assess fatigue safety of artificial heart valves in vivo”, says Francesco Iannaccone, Key Account Manager at FEops.

“FEops simulation technology has been a valuable addition to our R&D group at every step of our device development, providing crucial anatomical insights, preventing fatigue issues in the early design of our device, assisting with the development of appropriate fatigue bench tests, and finally giving additional confidence for a successful Topaz TTVR first-in-human through their simulated preoperative implantations”, Coralie Marchand, Senior Engineer R&D at TRiCares commented.

“This milestone will foster the future expansion of our portfolio of structural heart planning tools in the right heart and reinforces the unique value FEops brings in assisting valve manufacturers with its innovative simulation technology”, says Gianluca De Santis, FEA Services Director at FEops.

About FEops
Privately held FEops, headquartered in Gent, Belgium, is a digital health player offering cloud-based procedure planning solutions in the structural heart space. It’s FEops vision that combining digital twins with AI-enabled anatomical analyses generates data-driven insights aspiring to enhance and improve procedure planning and periprocedural guidance. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Partners and PMV. In December 2019, FEops has been awarded a grant of Euro 3.2 million from the European Innovation Council (EIC) accelerator programme.

www.feops.com

Contacts

Press
Matthieu De Beule, PhD
CEO
Tel: +32 9 292 80 30
Email: matthieu.debeule@feops.com

FEops


Release Versions

Contacts

Press
Matthieu De Beule, PhD
CEO
Tel: +32 9 292 80 30
Email: matthieu.debeule@feops.com

More News From FEops

Clinical Utility of FEops AI-enabled Predictive Pre-planning for LAAO Demonstrated in US

GENT, Belgium--(BUSINESS WIRE)--Data from the first US comprehensive single center experience at St Bernard’s Medical Center and Arrhythmia Research Group, presented at a Late-Breaking session at the AF Symposium 2024 in Boston, shows that Left Atrial Appendage Occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result in significantly improved procedural efficiency. The 178 patient US single center evaluation, led by Dr Devi Nair (St Bernard’s, Jonesboro, US) aimed to assess the...

FEops Partners with TeraRecon to Scale the Commercialization of FEops HEARTguide, its Digital Twin Solution for an Elevated Structural Heart Experience

GENT, Belgium--(BUSINESS WIRE)--FEops, a leader in personalized predictive planning for structural heart interventions, announced today its partnership with ConcertAI's TeraRecon, for the commercialization of FEops HEARTguide’s for Left Atrial Appendage (LAA) occlusion workflow, with a strong focus on the US market. "We are thrilled to join forces with TeraRecon and integrate our FEops HEARTguide™ solution into TeraRecon’s software," said Matthieu De Beule, CEO of FEops. "This collaboration is...

FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities

GENT, Belgium--(BUSINESS WIRE)--FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions. With this introduction, physicians don’t need to do the measurements manually anymore, which will help streamline their workflow and gain time. It’s not a black box, FEops still offers physicians the option for performing the analysis themselves. This new release, reinforced by the s...
Back to Newsroom